By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Salmeterol

Salmeterol

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|634 words

Salmeterol: Long-Acting Bronchodilator for Asthma and COPD

What is Salmeterol?

Salmeterol is a long-acting beta-2 adrenergic receptor agonist (LABA) used to treat breathing disorders. It belongs to a class of medications called bronchodilators that help open the airways in the lungs. Salmeterol is primarily prescribed for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Uses

Salmeterol has several approved medical uses:

Asthma maintenance therapy: Used as a controller medication to prevent asthma symptoms and reduce the frequency of asthma attacks when combined with an inhaled corticosteroid.

COPD management: Helps improve breathing and reduce exacerbations in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Submit Your Paper
GMJ_Submit_Banner

Exercise-induced bronchospasm prevention: Can be used to prevent breathing difficulties triggered by physical activity in patients with asthma.

Combination therapy: Often prescribed in fixed-dose combinations with inhaled corticosteroids like fluticasone for enhanced anti-inflammatory and bronchodilator effects.

How it works

Salmeterol works by binding to beta-2 adrenergic receptors in the smooth muscle cells of the airways. When activated, these receptors trigger a cascade that leads to muscle relaxation and airway dilation, making it easier to breathe. Unlike short-acting bronchodilators, salmeterol provides sustained bronchodilation for up to 12 hours due to its unique molecular structure that allows it to remain attached to the receptor for extended periods.

Side effects

Common side effects:

  • Headache
  • Throat irritation
  • Hoarseness or voice changes
  • Tremor or shakiness
  • Nervousness
  • Dizziness
  • Nausea
  • Upper respiratory tract infection

Serious side effects requiring immediate medical attention:

  • Paradoxical bronchospasm (sudden worsening of breathing)
  • Chest pain or rapid heart rate
  • Severe allergic reactions with rash, swelling, or difficulty breathing
  • Dangerously low potassium levels
  • Increased blood pressure

Warnings and precautions

Black box warning: Salmeterol may increase the risk of asthma-related death when used alone. It should only be used in combination with an inhaled corticosteroid and discontinued once asthma control is achieved.

Not for acute symptoms: Salmeterol is not a rescue medication and should never be used to treat sudden breathing problems or asthma attacks.

Cardiovascular conditions: Use with caution in patients with heart disease, high blood pressure, or irregular heart rhythms, as beta-agonists can affect heart function.

Pregnancy and breastfeeding: Classified as FDA pregnancy category C. Should be used during pregnancy only if benefits outweigh risks. Effects on breastfeeding infants are unknown.

Diabetes and electrolyte disorders: May cause elevated blood sugar levels and decreased potassium, requiring monitoring in susceptible patients.

Interactions

Beta-blockers: May counteract salmeterol’s bronchodilating effects and potentially cause severe bronchospasm in asthmatic patients.

MAO inhibitors and tricyclic antidepressants: Can potentiate cardiovascular effects of salmeterol, increasing risk of heart rhythm abnormalities.

Diuretics: May enhance potassium-lowering effects, potentially leading to dangerous electrolyte imbalances.

Other beta-agonists: Concurrent use may increase risk of cardiovascular side effects and should generally be avoided.

Strong CYP3A4 inhibitors: Medications like ketoconazole or ritonavir may increase salmeterol levels, raising the risk of systemic side effects.

Xanthine derivatives: Theophylline and similar medications may increase the likelihood of cardiovascular side effects when combined with salmeterol.

Corticosteroids: While often used together therapeutically, systemic steroids may enhance potassium-lowering effects.

Check interactions with the GMJ Interaction Checker

Dosage

For adults with asthma or COPD, the typical dose is one inhalation (50 micrograms) twice daily, approximately 12 hours apart. For exercise-induced bronchospasm prevention, one inhalation is usually taken 30 minutes before exercise, with no additional doses for at least 12 hours. The maximum recommended dose is two inhalations twice daily. Dosage should always be individualized by a healthcare provider based on disease severity, response to treatment, and other factors. Patients should not exceed the prescribed dose, as higher amounts do not provide additional benefit but may increase side effects.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Salmeterol." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/salmeterol/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Magnesium’s hidden role in insulin signalling: why the mineral matters for glucose control

Magnesium acts as a critical molecular switch in insulin signalling. New analysis…

Why the same bread raises blood sugar differently in different people

Researchers at the Weizmann Institute found that identical carbohydrate meals produce glucose…

Vitamin D dose response is not linear: Why shelf-picked supplements may not work as expected

Vitamin D supplements do not work the same way for everyone. Research…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Theophylline

By
Prof. Giorgi Pkhakadze
02/06/2026

Domperidone

By
Prof. Giorgi Pkhakadze
02/06/2026

Metronidazole

By
Prof. Giorgi Pkhakadze
02/06/2026

Montelukast

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up